Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04792502
Title Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Adam Olszewski

marginal zone B-cell lymphoma

follicular lymphoma


Lenalidomide + Mosunetuzumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.